A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, an Anti-TFPI Monoclonal Antibody for the Prophylactic Treatment of Hemophilia Α and B
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199766
Abstract: Introduction: Marstacimab is a human anti-TFPI monoclonal antibody currently in phase 3 development, intended for routine prophylaxis treatment to prevent or reduce the frequency of bleeding episodes in hemophilia A or B patients (with or… read more here.
Keywords: treatment; peak thrombin; weight; range ... See more keywords
Evaluation of the combined effects of emicizumab and marstacimab in plasma from Hemophilia A patients using thrombin generation assay
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4834
Abstract: Background: Patients with Hemophilia A (HA) may be treated with prophylactic emicizumab therapy, a bispecific monoclonal antibody that promotes coagulation by bridging factor IX (FIX) and factor X (FX). Marstacimab has been recently approved for… read more here.
Keywords: thrombin generation; generation; lag time; peak thrombin ... See more keywords